ClinicalTrials.gg
CompletedNCT06408948Updated Jul 22, 2024

A Study to Evaluate the Mass Balance of [14C]SHR7280 in Healthy Adult Volunteers

A Phase 1 interventional study of [14C]SHR7280 in Assisted Reproduction, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-07-22.

Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
6
Allocation
Not applicable
Ages
18 Years to 45 Years
Sex
All
01

Study summary

Evaluate the Mass Balance of [14C]SHR7280 in Healthy Adult Volunteers.

02

Conditions studied

  • Assisted Reproduction
03

In context

Lead sponsor

Jiangsu HengRui Medicine Co., Ltd. is the lead sponsor of 573 studies on the registry; 88 are open to participants now.

Of its 10 completed or terminated interventional studies of FDA-regulated products, 1 (10%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Sign the form prior to the trial and have a full understanding of the trial's procedures, content, and potential adverse reactions;
  2. Healthy adult females and males between 18 and 45 years;
  3. Body weight ≥50 kg(for male), body weight ≥45 kg(for female), and the (BMI) of 19 to 26 kg/m2;
  4. From the signing of the informed consent form until 12 months after the last administration, the subject (including partner) has no family planning and is willing to use the high-efficiency measures specified in the plan;
  5. The first three menstrual cycles for women were regular, with a menstrual cycle of 21-35 days, and no abnormal uterine bleeding occurred.

Exclusion criteria

Exclusion Criteria:

  1. Comprehensive physical examination, vital signs, laboratory tests (blood routine, blood biochemistry, coagulation function, urine analysis, fecal routine+occult blood, thyroid function), full chest X-ray, 12 lead , abdominal ultrasound, digital rectal examination, bilateral breast, uterus, and bilateral accessory ultrasound results that the researcher deems ;
  2. Serum testosterone (T) \<3.46 ng/mL during screening for male; serum follicle stimulating hormone (FSH) ≥ 25mIU/mL during screening period for female;
  3. Patients with >450 msec (male) and QTcF>470 msec (female) at the time of screening or baseline, or other clinically significant abnormalities determined by the researcher;
  4. surface antigen (HBsAg) positive, or anti virus (HCV) antibody positive, or (HIV) antigen/antibody combined test positive, or Treponema pallidum antibody positive;
  5. Screening period or baseline period (D-1) serum pregnancy testing (serum β- The HCG test )result is positive for female;
  6. Women use the following methods during screening visits: sustained-release intrauterine devices, sustained-release contraceptives (subcutaneous implants, vaginal rings, microspheres, and microcapsules); Before screening, use long-acting contraceptive pills (using medroxyprogesterone acetate for 3 months and other injections for 1 month), oral contraceptives (such as short acting, long-acting, or emergency contraceptives) for 2 months before screening, and contraceptive patches for 1 month before screening; Special circumstances to be determined by the researcher;
  7. Abuse of drugs or use of soft drugs (such as marijuana) in the three months prior to screening, or use of hard drugs (such as amphetamines, phencyclidine, etc.) in the year prior to screening; Or screening period urine drug test positive individuals, including: morphine, methamphetamine (methamphetamine), ketamine, ecstasy (methamphetamine), marijuana (tetrahydrocannabidiol acid);
  8. Using any prescription, over-the-counter, herbal or dietary supplements before the first two screening weeks;
  9. Women with a history of pregnancy, miscarriage, childbirth, or breastfeeding in the 6 months prior to screening;
  10. Any clinical history of serious diseases or conditions that the researcher believes may affect the trial results, including but not limited to a history of circulatory, endocrine, nervous, digestive, urinary, or blood, immune, mental, and metabolic diseases;
  11. Individuals with a history of malignant tumors or suspected to have sex hormone dependent malignant tumors;
  12. Allergic constitution, or suspected allergy to any ingredient in SHR7280 formulation;
  13. Individuals who have undergone any surgery in the first 3 months prior to screening, have not yet recovered after surgery, or are expected to have surgery or hospitalization plans during the trial period;
  14. Perianal diseases with hemorrhoids or periodic/ongoing rectal bleeding; The subject is unable to swallow, or has a history of gastrointestinal dysfunction such as irritable bowel syndrome, inflammatory bowel disease, or has undergone surgery such as gastrectomy, which the researcher determines may affect drug absorption;
  15. Habitual constipation or diarrhea;
  16. Have a history of severe vomiting;
  17. Individuals with a history of smoking in the first three months prior to screening (average daily smoking>5 cigarettes);
  18. In the three months before screening, the average daily intake of alcohol exceeded 25 g (for example, 750 mL of beer, 250 mL of wine, or 50 mL of Baijiu); Or those with an alcohol breath test result of ≥ 20 mg/dl during the screening period;
  19. Habitually drinking grapefruit juice or excessive amounts of tea, coffee, and/or caffeinated beverages, or unable to quit during the trial period;
  20. Select clinical trial participants who have participated in any other drug or medical device within the first 3 months or within 5 half-lives of the drug (depending on whether the drug is administered or the device is used);
  21. Those who receive the vaccine within 2 weeks before the first administration or within 1 month after the last administration during the study period;
  22. Individuals who have donated (or lost) blood and have donated (or lost) more than 400 mL of blood, or have received blood transfusions in the first 3 months prior to screening;
  23. Engaged in workers who require long-term exposure to radioactive conditions; Or select individuals who have been significantly exposed to radiation (chest/abdominal CT ≥ 2 times, or other types of X-ray examinations ≥ 3 times) or have participated in radiopharmaceutical labeling trials in the one year prior to screening;
  24. Difficulty swallowing, difficulty in venous blood collection, or physical condition unable to withstand blood collection; Or subjects who are expected to be unable to complete the entire trial follow-up;
  25. According to the researcher's judgment, the subjects may have factors that affect drug absorption, distribution, metabolism, and excretion, or may reduce compliance, or other factors that are not suitable for participation in this study.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
6 participants (actual)

Study arms

  • Experimental
    [14C]SHR7280

    Drug: [14C]SHR7280

Interventions

  • Patients will receive single dose of orally \[14C\]SHR7280 on Day 1.

06

What researchers measure

Primary outcomes

  1. Cumulative recovery and recovery rate of total radioactive substance in urine and feces

    Time frame: 0-240 hours

  2. Percentage of parent drug and its metabolites in plasma as a percentage of total radioactive exposure (%AUC)

    Time frame: 0-120 hours

  3. Percentage of parent drug and its metabolites in urine and feces as a percentage of administered dose (%Dose)

    Time frame: 0-240 hours

  4. Radioactivity Tmax

    Time frame: 0-120 hours

  5. Radioactivity Cmax

    Time frame: 0-120 hours

  6. Radioactivity AUC

    Time frame: 0-120 hours

  7. Radioactivity t1/2

    Time frame: 0-120 hours

  8. Radioactivity CL/F

    Time frame: 0-120 hours

  9. Radioactivity Vz/F

    Time frame: 0-120 hours

  10. Total radioactivity ratio for blood/plasma

    Time frame: 0-48 hours

Secondary outcomes

  1. Plasma SHR7280: Tmax

    Time frame: 0-120 hours

  2. Plasma SHR7280: Cmax

    Time frame: 0-120 hours

  3. Plasma SHR7280: AUC

    Time frame: 0-120 hours

  4. Plasma SHR7280: t1/2

    Time frame: 0-120 hours

  5. Plasma SHR7280: CL/F

    Time frame: 0-120 hours

  6. Plasma SHR7280: Vz/F

    Time frame: 0-120 hours

  7. Plasma SHR7280: λz

    Time frame: 0-120 hours

  8. AEs and SAEs

    Time frame: Screening to 10 days

07

Study locations

1 site
  • The First Affiliated Hospital of Suzhou University
    Suzhou, Jiangsu 215008, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2024 to primary completion in Jul 2024, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 7, 2024
First posted
May 10, 2024
StartActual
Jun 7, 2024
Primary completionActual
Jul 6, 2024
CompletionActual
Jul 6, 2024
Last update
Jul 22, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 22, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06408948
Responsible party
Sponsor
First posted
May 10, 2024
Start date
Jun 7, 2024
Primary completion
Jul 6, 2024
Completion
Jul 6, 2024
Last update
Jul 22, 2024

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: GnRH Antagonist SHR7280

Start the discussion